AnGes MG, Inc. is a biopharmaceutical company founded December 1999 based on an innovative discovery by researchers of Osaka University. The Company specializes in R&D and practical application of genetic medicine. At present, the Company is engaged in developing two new medicines: the Hepatocyte Growth Factor (HGF) genetic medicine which improves blood circulation by regenerating blood vessels, and an NFkB decoy which controls various inflammations. The HVJ Envelope Vector technology is being developed through the Company's subsidiary, GenomIdea Inc.